RAC-US by RAPS Actual Free Exam Q&As

Question 1

Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?

A. Subject is hospitalized for the purpose of product administration. B. Subject is hospitalized due to complications of the product administration. C. Subject's hospitalization is prolonged during the clinical trial. D. Subject's hospitalization is due to an unscheduled hip operation.

Discussion 0

Correct Answer: A Vote an answer

Question 2

A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre- specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?

A. Consult with the legal department to discuss the best course of action. B. Review the regulatory guidelines to determine how to proceed. C. Notify the regulatory authority regarding Its obligation to honor the commitment to approve the application. D. Request a meeting with the regulatory authority to discuss the application.

Discussion 0

Correct Answer: D Vote an answer

Question 3

Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?

A. A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation B. A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use C. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product D. A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation

Discussion 0

Correct Answer: A Vote an answer

Question 4

A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?

A. Label the product for use in appropriate populations. B. Promote off-label use to a carefully selected patient population. C. Delay product launch until required studies are completed. D. Educate patients and healthcare providers on how to use the product

Discussion 0

Correct Answer: B Vote an answer

Question 5

An inspection of a manufacturing site determines that a number of manufacturing changes have been implemented without obtaining the necessary regulatory clearance. Which of the following actions should the regulatory affairs professional complete FIRST?

A. Establish validation procedures. B. Assess the impact of the changes. C. Review the stability data for the changes. D. Stop product manufacturing.

Discussion 0

Correct Answer: D Vote an answer

Question 6

Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?

A. Train employees on all regulatory compliance processes using state-of-the-art systems. B. Develop documented procedures for regulatory compliance processes and train personnel. C. Train all new employees on regulatory compliance processes and assign a mentor to them. D. Document any failure to follow regulatory compliance processes in employee performance reviews.

Discussion 0

Correct Answer: B Vote an answer

Question 7

During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?

A. Contact the regulatory authority to discuss its findings. B. Contact the regulatory authority to argue that its conclusions are wrong. C. Wait for the regulatory authority's final publication on its findings. D. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.

Discussion 0

Correct Answer: A Vote an answer

Question 8

What are the MOST important elements that global regulatory agencies want to know before approving a new product for sale in their countries?

A. Quality and effectiveness B. Safety and failure risk C. Quality and failure risk D. Safety and effectiveness

Discussion 0

Correct Answer: D Vote an answer

Question 9

A regulatory authority announces an inspection of a regulatory affairs professional's facility during a holiday season when most of the staff Is not available. What is the MOST practical approach to this dilemma?

A. Inform the authority that the time is not suitable and request a new time B. Arrange for an inspection without all intended personnel. C. Insist that key personnel be available for the inspection. D. Negotiate with colleagues and the authority to find a better time.

Discussion 0

Correct Answer: D Vote an answer

Question 10

Which of the following is the PRIMARY purpose of an audit report?

A. To carry out a complete review of product applications B. To train sales representatives C. To define how to prepare new product submissions D. To document compliance history

Discussion 0

Correct Answer: D Vote an answer

RAPS Regulatory Affairs Certification (RAC) US - RAC-US Exam Practice Test